| IV-087 Mélanie Wilbaux How to handle population pharmacokinetics modeling in the context of a regulatory submission for a compound already well-characterized in other settings? A case-study with nivolumab in urothelial cancer. Thursday 15:00-16:30 |
| IV-087 Mélanie Wilbaux How to handle population pharmacokinetics modeling in the context of a regulatory submission for a compound already well-characterized in other settings? A case-study with nivolumab in urothelial cancer. Thursday 15:00-16:30 |